$Meta Platforms(META.US$ As I understand, institutions bitchslapped meta for following reasons:
1. Capital Expenditures - Meta is ramping up its investment in AI, raising its 2024 spending forecast to $35 billion to $40 billion, up from $30 billion to $37 billion. They're betting big on future tech.
2. Revenue Forecast - For Q2, Meta expects revenue between $36.5 billion and $39 billion. The midpoint, $37.75 billion, represents an 18% year-o...
1. Capital Expenditures - Meta is ramping up its investment in AI, raising its 2024 spending forecast to $35 billion to $40 billion, up from $30 billion to $37 billion. They're betting big on future tech.
2. Revenue Forecast - For Q2, Meta expects revenue between $36.5 billion and $39 billion. The midpoint, $37.75 billion, represents an 18% year-o...
4
2
$JPMorgan(JPM.US$ just out - $TG Therapeutics(TGTX.US$ BUY PT 25 VA contract Unequivocal win for TGTX on couple fronts 👍 few details still to be worked out but looks like 40 million a year new durable revenue stream for $TG Therapeutics(TGTX.US$
2
$Eli Lilly and Co(LLY.US$ two late-stage trials evaluating a 10 mg or 15 mg injection of tirzepatide — the weight-loss drug marketed in the U.S. as Zepbound — reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
3
1
$TG Therapeutics(TGTX.US$ short interest still trending up - $Viking Therapeutics(VKTX.US$ - short interest down some
4
$SPDR S&P Biotech ETF(XBI.US$ $iShares Biotechnology ETF(IBB.US$
Observations from $VINC (-60% AH):
1- When companies tout "strong safety profile", often means efficacy is a big fat zero
2- Phrases like "dose dependent clinical activity" set the bar low
3- "Promising" doesn't necessarily refer to SP
Stay skeptical, my friends.
Observations from $VINC (-60% AH):
1- When companies tout "strong safety profile", often means efficacy is a big fat zero
2- Phrases like "dose dependent clinical activity" set the bar low
3- "Promising" doesn't necessarily refer to SP
Stay skeptical, my friends.
2
$SPDR S&P Biotech ETF(XBI.US$ $iShares Biotechnology ETF(IBB.US$
Mike on biotech's correlation with interest rates:
"Biotech is essentially a call option on $iShares 20+ Year Treasury Bond ETF(TLT.US$
Biotech bulls need inflation and rates to move lower for resumption of a real bull market.
XBI is likely to remain range-bound - or worse - until inflation convincingly moves lower.
Hopefully we can grind out reasonable returns in the meantime by buying the right stocks, but we will b...
Mike on biotech's correlation with interest rates:
"Biotech is essentially a call option on $iShares 20+ Year Treasury Bond ETF(TLT.US$
Biotech bulls need inflation and rates to move lower for resumption of a real bull market.
XBI is likely to remain range-bound - or worse - until inflation convincingly moves lower.
Hopefully we can grind out reasonable returns in the meantime by buying the right stocks, but we will b...
5
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
3
$Merck & Co(MRK.US$'s $11.5 bil bet on Acceleron in 2021 pays off w/ FDA approval of Wenrevair for PAH,
When deal closed in 2021 analysts were projecting peak sales of $2.2 bil for sotatercept (Wenrevair), now estimates are as high as $5-$7.5 bil,
Looks like MRK got a great deal but Wenrevair would still only cover about 20%-25% of Keytruda's $25 bil in rev from LOE in 2028,
MRK's made 4 other big acquisitions since 2021: $680 mil for $HARP, $610 mil for Caraway, $1.3 bil for Imago and the big...
When deal closed in 2021 analysts were projecting peak sales of $2.2 bil for sotatercept (Wenrevair), now estimates are as high as $5-$7.5 bil,
Looks like MRK got a great deal but Wenrevair would still only cover about 20%-25% of Keytruda's $25 bil in rev from LOE in 2028,
MRK's made 4 other big acquisitions since 2021: $680 mil for $HARP, $610 mil for Caraway, $1.3 bil for Imago and the big...
2
$X4 Pharmaceuticals(XFOR.US$ patience you can't buy. Bought a big chunk of shares around 0.6 area and sitting on it patiently when others were selling indiscriminately on fear.
My target is 2-2.5 before or after FDA approval.
I think this is a very conservative target with 100 million non dilutive cash via voucher upon FDA approval
Technically, it trades under cash
Two catalysts
FDA decision
CN data
My target is 2-2.5 before or after FDA approval.
I think this is a very conservative target with 100 million non dilutive cash via voucher upon FDA approval
Technically, it trades under cash
Two catalysts
FDA decision
CN data
Impressive AHs action in $Astera Labs(ALAB.US$ . I tossed out offers right after the close just in case it went higher & they just got hit. Still a small position for me (~4.25% total wghting) but will be eying this for a setup in the coming days/weeks to get a more normal sized position. Fills -
1